REG - ReNeuron Group plc - Share Purchase by Executive Chairman

ReNeuronAnnouncement

23/01/2023 15:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230123:nRSW5891Na&default-theme=true

RNS Number : 5891N  ReNeuron Group plc  23 January 2023

ReNeuron Group plc

("ReNeuron" or "the Group")

 

Share Purchase by Executive Chairman

 

ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome
technologies, announces that Iain Ross, Executive Chairman of the Company, has
today purchased 100,000 of the Company's ordinary shares of 1p each ("Ordinary
Shares").

 

 Name       Title               Number of Ordinary Shares purchased  Resulting beneficial interest in the Company's Ordinary Shares  Percentage of Company's Total Voting Rights
 Iain Ross  Executive Chairman  100,000                              200,000                                                         0.350%

 

 
ENDS

 

 

 

Enquiries:

 

 ReNeuron                                                  www.reneuron.com/investors (http://www.reneuron.com/investors)
 Iain Ross, Executive Chairman                             Via Walbrook PR
 John Hawkins, Chief Financial Officer

 Liberum Capital Limited (NOMAD and Joint Broker)          +44 (0)20 3100 2000

 Phil Walker (Investment Banking)

 Richard Lindley (Investment Banking)

 Ben Cryer (Investment Banking)

 Allenby Capital Limited (Joint Broker)                    +44 (0)20 3328 5656
 James Reeve/George Payne (Corporate Finance)
 Stefano Aquilino (Sales & Corporate Broking)

 Walbrook PR (Media & Investor Relations)                  +44 (0)20 7933 8780 or reneuron@walbrookpr.com
                                                           (mailto:reneuron@walbrookpr.com)
 Paul McManus / Alice Woodings  +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About ReNeuron

 

ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug
delivery platform with customisable cellular targeting capabilities for the
delivery of complex drug modalities.

 

Through the generation of several unique and scalable exosome producer cell
lines, our CustomEX™ platform can be optimised for specific tissues targets
and payloads leading to improvements in therapeutic outcome and a reduction in
off-target effects. ReNeuron offers a delivery mechanism for a variety of
payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its
conditionally immortalised induced pluripotent stem cell (iPSC) platform, the
Company can make allogeneic tissue cells of choice and has the potential to
produce exosomes with tissue specific targeting ability.

 

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.
For further information visit www.reneuron.com (http://www.reneuron.com/)

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

(Disclosure in relation to ordinary shares purchased by Directors and PDMRs)

 

 

  1     Details of the person discharging managerial responsibilities / person closely
        associated
 a)     Name                                                           Iain Gladstone Ross
 2      Reason for the notification
 a)     Position/status                                                Executive Chairman and Director
 b)     Initial notification /Amendment                                Initial notification
 3      Details of the issuer, emission allowance market participant, auction
        platform, auctioneer or auction monitor
 a)     Name                                                           ReNeuron Group plc
 b)     LEI                                                            2138003TU12CQ5TZO137
 4      Details of the transaction(s): section to be repeated for (i) each type of
        instrument; (ii) each type of transaction; (iii) each date; and (iv) each
        place where transactions have been conducted
 a)     Description of the financial instrument, type of instrument    Ordinary Shares 1p

        Identification code                                            RENE - GB00BF5G6K95
 b)     Nature of the transaction                                      Acquisition of ordinary shares
 c)     Price(s) and volume(s)                                          Price(s)     Volume(s)

                                                              9.5p          100,000

 d)     Aggregated information                                         100,000 ordinary shares at an average price of 9.5p at a total value of

                                                                     £9,500

 e)     Date of the transaction                                        23 January 2023
 f)     Place of the transaction                                       London Stock Exchange AIM Market

d)

 

Aggregated information

100,000 ordinary shares at an average price of 9.5p at a total value of
£9,500

e)

Date of the transaction

23 January 2023

f)

Place of the transaction

London Stock Exchange AIM Market

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFESLTIVFIV